schizoaffective disorder

Search with Google Search with Bing
Information
Disease name
schizoaffective disorder
Disease ID
DOID:5418
Description
"A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality." [url:http\://en.wikipedia.org/wiki/Schizoaffective_disorder, url:http\://www.nlm.nih.gov/medlineplus/ency/article/000930.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT05660070 Active, not recruiting N/A Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness July 1, 2022 December 31, 2024
NCT05658510 Active, not recruiting Phase 3 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) November 21, 2022 March 30, 2025
NCT03829280 Active, not recruiting N/A Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM) April 4, 2019 April 2025
NCT03896438 Active, not recruiting N/A Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2 July 1, 2019 April 2024
NCT01409109 Active, not recruiting Database Registry for Neural Network Biomarkers in Psychosis March 2010 May 2025
NCT01941251 Active, not recruiting N/A Navigated αTMS in Treatment-resistant Schizophrenia March 2013 December 2025
NCT00512070 Active, not recruiting N/A Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine July 2007 December 2025
NCT00057135 Completed N/A Improving Antipsychotic Adherence Among Patients With Serious Mental Illness November 2002 September 2006
NCT00057707 Completed Phase 1 Effects of Modafinil on Brain Function in Patients With Schizophrenia March 26, 2003 June 16, 2017
NCT00061802 Completed Phase 4 Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder June 2003 February 2004
NCT00088465 Completed Phase 3 Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder August 2004 December 2010
NCT00090012 Completed Phase 4 Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder July 2004 March 2006
NCT00094640 Completed Phase 1 Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
NCT00095524 Completed Phase 3 Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder March 2004 August 2006
NCT00100776 Completed Phase 4 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder September 2003 November 2005
NCT00108199 Completed N/A Generalization of Training in Schizophrenia October 2001 September 2004
NCT00119574 Completed N/A Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP) January 2002 December 2004
NCT00132314 Completed Phase 3 Long-Acting Injectable Risperidone in the Treatment of Schizophrenia September 2006 September 2009
NCT00139906 Completed Phase 2 Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia August 2005 October 2006
NCT00139919 Completed Phase 2 Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder January 2006 October 2007
NCT00141479 Completed Phase 2 To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox May 2005 November 2006
NCT00148083 Completed Phase 3 Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia September 2005 March 2006
NCT00156637 Completed N/A A Study of Strategies to Improve Schizophrenia Treatment June 2005 March 2008
NCT00156715 Completed Phase 4 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder March 2004 October 2008
NCT00159770 Completed Phase 3 Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients November 2001 September 2004
NCT00167310 Completed Phase 2 Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation September 2005 December 2015
NCT00169052 Completed N/A Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People September 2001 August 2006
NCT00176423 Completed Phase 4 Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia May 2002 December 2006
NCT00177008 Completed Phase 4 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety March 2004 January 2007
NCT00177177 Completed N/A L-carnosine for Schizophrenia March 2004 December 2007
NCT00177580 Completed Phase 4 Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin July 2003 July 2007
NCT00178971 Completed Phase 3 Serotonin 1A Agonists and Cognition in Schizophrenia January 2003 October 2004
NCT00179062 Completed N/A Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder February 2000 June 2007
NCT00179231 Completed N/A Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia May 2000 February 2004
NCT00190749 Completed Phase 4 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder October 2003 June 2008
NCT00202293 Completed Phase 4 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features October 1, 2001 November 1, 2015
NCT00206102 Completed Phase 4 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder September 2003 October 2008
NCT00206544 Completed Phase 2 Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? January 2004 December 2007
NCT00206557 Completed Phase 2 The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study October 2002 April 2007
NCT00206570 Completed Phase 2 Clinical Estradiol Trial in Women With Schizophrenia January 2001 December 2004
NCT00208143 Completed Phase 4 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia November 2003 December 2005
NCT00208169 Completed Phase 4 Abilify Therapy for Reducing Comorbid Substance Abuse March 2005 June 2007
NCT00495118 Completed Phase 3 A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. October 2001 March 2005
NCT00007774 Completed Phase 4 To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia March 1998
NCT00018629 Completed Phase 2 Cognitive - Behavioral Therapy May 2000 April 2005
NCT00018642 Completed N/A Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder April 1997 March 2002
NCT00034801 Completed Phase 4 Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia September 2001 March 2003
NCT00036361 Completed Phase 3 Broad Effectiveness: Study With Aripiprazole July 2002 January 2003
NCT00051233 Completed Phase 2 Treatment of Schizophrenia Through Internet-Based Psychoeducation January 2003 January 2005
NCT01786239 Completed N/A Omega-3 Dietary Supplements in Schizophrenia May 2013 September 2015
NCT01786369 Completed Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. February 2013 April 2015
NCT01788774 Completed Phase 1 Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths April 2013 February 2014
NCT01793935 Completed N/A Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia April 2013 July 7, 2016
NCT01794897 Completed Phase 4 Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia February 2013 September 2016
NCT01822418 Completed Phase 4 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) January 2013 December 2015
NCT01828931 Completed N/A Lifestyle Intervention for Diabetes and Weight Management in Psychosis December 2012 November 2015
NCT01855074 Completed Phase 4 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders November 2007 February 2009
NCT01866098 Completed N/A Naltrexone for Antipsychotic-Induced Weight Gain May 2013 April 7, 2019
NCT01875822 Completed Phase 1/Phase 2 Open-label Study of Curcumin C-3 Complex in Schizophrenia June 2009 May 2012
NCT01878513 Completed N/A Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis September 23, 2009 July 31, 2018
NCT01880255 Completed N/A rTMS for Working Memory Deficits in Schizophrenia June 2013 January 7, 2019
NCT01884025 Completed N/A Get Moving and Get Well - Pilot Study June 2013 August 2015
NCT01888107 Completed Phase 3 Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder January 2005 April 2007
NCT01915017 Completed N/A Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia April 2008 July 2013
NCT01926613 Completed N/A Thinking Skills for Work in Severe Mental Illness April 2006 October 2011
NCT01945333 Completed N/A Personalized and Scalable Cognitive Remediation Approaches September 2013 March 20, 2019
NCT01952041 Completed N/A A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia March 13, 2015 August 7, 2017
NCT01963676 Completed N/A Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia January 2014 October 2014
NCT01969500 Completed N/A Development of a Mobile System for Self-management of Schizophrenia (SOS) November 2015 February 2017
NCT01975584 Completed N/A Neuroendocrine and Immune Response to Stress in Schizophrenia September 2013 June 2018
NCT01981759 Completed Phase 4 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions February 2014 October 2017
NCT01992393 Completed N/A Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) September 2013 September 2015
NCT01992913 Completed N/A Building Employment Skills Through Therapy for Veterans June 12, 2015 August 31, 2020
NCT01999309 Completed Phase 3 Simvastatin Addition for Patients With Recent-onset Schizophrenia October 2013 December 19, 2019
NCT02032680 Completed N/A Comparison of E-health vs. In-person Multi-Family Group (MFG) August 19, 2015 September 30, 2018
NCT02034253 Completed Glutamate, Brain Connectivity and Duration of Untreated Psychosis January 2014 November 2018
NCT02034474 Completed Phase 4 Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia February 2014 February 6, 2017
NCT02055287 Completed Phase 1 Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder March 2013 June 2014
NCT02069392 Completed N/A Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia January 2015 June 2017
NCT02074319 Completed Phase 1 RCT of Methotrexate Added to Treatment As Usual in Schizophrenia December 2013 August 2015
NCT02075528 Completed Phase 4 Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER July 2009 July 2012
NCT02085447 Completed N/A A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness May 2014 December 2016
NCT02090335 Completed N/A Health Promotion and Fitness for Younger and Older Adults With SMI May 2007 May 2013
NCT02091388 Completed Phase 1 Bioavailability of LY03004 and Risperdal® Consta® September 2014 January 2015
NCT02124811 Completed Phase 4 Minocycline Augmentation to Clozapine February 2015 November 2016
NCT02131116 Completed N/A Integrated Metacognitive Therapy in First Episode Psychosis May 2014 December 2017
NCT02131129 Completed N/A rTMS in First Episode Psychosis April 30, 2014 December 2016
NCT02137993 Completed Phase 4 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia March 2012 May 2013
NCT02160249 Completed N/A RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) September 2015 May 8, 2017
NCT02186769 Completed Phase 1 An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder July 2014 April 2015
NCT02188121 Completed Phase 4 Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients February 2015 October 2021
NCT02188732 Completed N/A Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes January 2015 July 31, 2021
NCT02199743 Completed Phase 4 Lurasidone Effects on Tissue Glutamate in Schizophrenia February 2013 June 2016
NCT02224430 Completed Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors August 2014 December 31, 2019
NCT02237235 Completed Phase 2 Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia August 2014 August 2017
NCT02267070 Completed N/A Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode November 2013 July 2017
NCT02308956 Completed Phase 3 Task Sharing for the Care of Severe Mental Disorders in a Low-income Country March 2015 November 16, 2017
NCT02326389 Completed N/A Exercise and Cognitive Training May 2015 November 2017
NCT02334228 Completed N/A Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness September 2006 August 2009
NCT02334280 Completed N/A Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI September 2009 May 2013
NCT02354001 Completed Phase 4 Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia April 2011 January 2019
NCT02360228 Completed N/A STimulation to Improve Auditory haLLucinations May 2015 February 2017
NCT02360813 Completed N/A Cognitive Remediation Therapy Within a Secure Forensic Setting August 2014 January 2017
NCT02364544 Completed N/A Improving Care and Reducing Cost Study April 2013 June 2015
NCT02386605 Completed N/A Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers March 28, 2016 June 30, 2020
NCT02398279 Completed N/A L-arginine add-on Therapy in Patients With Schizophrenia June 2011 April 2013
NCT02411526 Completed Phase 1 Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia February 2015 September 2015
NCT02415764 Completed Phase 1 OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant June 2015 March 2016
NCT02417142 Completed Phase 4 Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia September 2014 July 2020
NCT02421965 Completed N/A Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness June 2015 December 2017
NCT02453217 Completed N/A The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial March 31, 2016 January 31, 2019
NCT02504151 Completed Phase 2 Cannabidiol Treatment in Patients With Early Psychosis January 28, 2016 March 9, 2018
NCT02566057 Completed N/A Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis July 10, 2014 December 31, 2017
NCT02573168 Completed N/A Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics January 2016 September 2020
NCT02576613 Completed N/A Modified Psychodynamic Psychotherapy for Patients With Schizophrenia October 2015 December 2022
NCT02582736 Completed Antipsychotics and Risk of Hyperglycemic Emergencies April 2012 December 2012
NCT02593058 Completed N/A Positive Emotions Program for Schizophrenia (PEPS) February 1, 2016 December 31, 2018
NCT02636842 Completed Phase 1 A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder December 2015 June 2016
NCT02640300 Completed Phase 4 Switching Antipsychotics: Abrupt Discontinuation Versus Overlap May 1999 July 2004
NCT02642029 Completed N/A Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study February 18, 2016 June 14, 2019
NCT02664129 Completed N/A Video as a Tool to Improve Insight in Schizophrenia December 8, 2015 December 30, 2018
NCT02775864 Completed Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia July 2015 June 2018
NCT02782442 Completed N/A Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) September 1, 2016 March 12, 2022
NCT02787122 Completed N/A Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia January 1, 2014 December 31, 2017
NCT02810964 Completed Phase 2 Sulforaphane to Reduce Symptoms of Schizophrenia February 22, 2017 November 11, 2019
NCT02815813 Completed N/A Lifestyle Intervention for Young Adults With Serious Mental Illness July 3, 2017 May 31, 2022
NCT02819349 Completed N/A Texting for Relapse Prevention March 12, 2018 April 9, 2019
NCT02823041 Completed N/A Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode October 13, 2016 June 30, 2023
NCT02869334 Completed N/A Remediation of Auditory Recognition in Schizophrenia With tDCS June 2016 January 31, 2020
NCT02901587 Completed Phase 1 Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder September 2016 April 18, 2018
NCT02921243 Completed Schizophrenia and the Gut Microbiome October 1, 2016 June 18, 2019
NCT02930005 Completed Phase 2 Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders August 7, 2015 October 6, 2016
NCT02978599 Completed Phase 1 Clinical Trial of AVL-3288 in Schizophrenia Patients November 2016 November 2, 2018
NCT03037983 Completed N/A Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation August 1, 2017 July 18, 2019
NCT03043820 Completed Phase 3 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder August 2016 July 1, 2021
NCT03049813 Completed N/A Virtual Reality Job Interview Training in Severe Mental Illness June 1, 2017 July 31, 2022
NCT03050853 Completed N/A The Appeal and Impact of E-cigarettes in Smokers With SMI March 1, 2017 January 31, 2021
NCT03062267 Completed N/A Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness October 1, 2017 May 31, 2020
NCT03076346 Completed Neural Biomarkers of Clozapine Response September 1, 2017 December 31, 2020
NCT03079024 Completed N/A Minnesota Community-Based Cognitive Training in Early Psychosis May 19, 2017 March 26, 2022
NCT03179696 Completed N/A Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia August 15, 2016 October 31, 2018
NCT03197168 Completed N/A Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile March 2014 March 2016
NCT03288779 Completed N/A Theta Burst Stimulation for Schizophrenia October 24, 2017 June 30, 2018
NCT03316664 Completed N/A Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis June 1, 2018 August 31, 2021
NCT03370341 Completed N/A Stimulating the Brain to Improve Self-Awareness December 1, 2017 December 1, 2019
NCT03388554 Completed N/A The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schizophrenia July 2016 March 2, 2018
NCT03390491 Completed N/A OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis November 1, 2018 July 31, 2021
NCT03404219 Completed N/A Motivation and Skills Support (MASS) November 1, 2018 May 11, 2020
NCT03409393 Completed N/A Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis January 22, 2018 August 1, 2018
NCT03510741 Completed Phase 2 Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. January 1, 2019 March 30, 2021
NCT03526354 Completed Phase 4 Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder March 19, 2018 February 29, 2024
NCT03559426 Completed Phase 4 Research Into Antipsychotic Discontinuation and Reduction Trial March 24, 2016 March 10, 2022
NCT03568500 Completed Phase 4 A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic May 21, 2018 September 6, 2019
NCT03571685 Completed N/A Sustainable Early Episode Clinic Study (SEEC) January 31, 2017 December 20, 2019
NCT03576976 Completed N/A Improving Accessibility and Personalization of CR for Schizophrenia July 16, 2018 May 30, 2022
NCT03617783 Completed Phase 4 Prebiotic Treatment in People With Schizophrenia - Pilot Study July 18, 2019 April 5, 2022
NCT03621774 Completed N/A Mobile CBT for Negative Symptoms March 27, 2019 August 31, 2022
NCT03701100 Completed N/A The Effects of Bimodal tDCS on Illness Severity, Insight, Functional Outcomes, Neurocognition and HRV in Schizophrenia July 17, 2017 September 21, 2018
NCT03751488 Completed Phase 1 A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients December 12, 2018 July 24, 2019
NCT03757988 Completed N/A Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life December 6, 2018 September 11, 2019
NCT03848234 Completed Phase 3 Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder December 4, 2015 July 29, 2016
NCT03860597 Completed Phase 4 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia April 1, 2018 March 31, 2021
NCT03873337 Completed N/A Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI) April 22, 2019 January 31, 2022
NCT03880227 Completed N/A Improving Visual Attention in Schizophrenia March 25, 2019 March 4, 2020
NCT03921450 Completed N/A Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) March 25, 2019 February 10, 2023
NCT03930251 Completed N/A Cognitive Remediation for Coordinated Specialty Care June 1, 2019 December 31, 2023
NCT04011280 Completed Phase 4 Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness August 12, 2019 March 4, 2022
NCT04038788 Completed N/A Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia October 24, 2018 May 17, 2019
NCT04068467 Completed N/A Evaluation of mHealth for Serious Mental Illness January 6, 2020 May 1, 2021
NCT04173572 Completed N/A Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial December 20, 2019 March 23, 2022
NCT04251195 Completed N/A Verbal Memory Training Using Virtual Reality in Schizophrenia February 12, 2019 February 17, 2023
NCT04268303 Completed Phase 3 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia January 24, 2020 May 6, 2020
NCT04284813 Completed N/A Families With Substance Use and Psychosis: A Pilot Study September 24, 2020 July 7, 2022
NCT04418011 Completed N/A Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders November 30, 2020 February 2, 2023
NCT04545294 Completed N/A Theta tACS During Working Memory Training: A Pilot Study of the Effects on Negative Symptoms of Schizophrenia August 14, 2019 April 10, 2020
NCT04673851 Completed N/A Horyzons: Implementation in Clinical Practice January 19, 2021 August 31, 2023
NCT04783285 Completed N/A Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders March 29, 2021 December 31, 2021
NCT04870710 Completed N/A Feasibility Electrical Stimulation Study for Visual Hallucinations October 1, 2020 January 2, 2022
NCT04874974 Completed N/A Feasibility of a Novel Process-based Treatment for Patients With Psychosis May 10, 2021 September 23, 2023
NCT05105542 Completed Phase 2 M1 Schizophrenia PET Study April 20, 2021 October 31, 2023
NCT05712928 Completed N/A eMove - Dance/Movement Therapy Study June 29, 2021 December 31, 2022
NCT05746455 Completed N/A Motivation Skills Training for Schizophrenia May 30, 2023 December 31, 2023
NCT05779241 Completed Phase 3 Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 April 13, 2023 December 1, 2023
NCT05784948 Completed N/A Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis April 8, 2020 June 9, 2021
NCT00212771 Completed Phase 3 Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) September 2004 October 2006
NCT00212784 Completed Phase 3 Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) September 4, 2003 March 15, 2006
NCT00215579 Completed Phase 4 Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence April 2004 April 2006
NCT00222235 Completed Phase 2/Phase 3 Adjunctive Treatment for Decreasing Symptoms of Schizophrenia January 2000 June 2004
NCT00222794 Completed Phase 4 A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia November 2003 July 2006
NCT00222807 Completed Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus August 2003 March 2016
NCT00223418 Completed N/A Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills January 2004 June 2007
NCT00224822 Completed Phase 4 The Effects of Aripiprazole on Patients With Metabolic Syndrome March 2004 March 2007
NCT00231335 Completed Phase 4 Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia March 2006 July 2007
NCT00237796 Completed N/A Functional Rehabilitation of Older Patients With Schizophrenia February 2005 January 2009
NCT00237809 Completed Phase 3 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia September 2002 September 2012
NCT00237848 Completed Phase 3 D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia February 2005
NCT00246259 Completed Phase 4 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis October 2004 December 2008
NCT00253110 Completed Phase 4 A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder May 1996 September 1998
NCT00261716 Completed Phase 3 Motivational Interviewing to Improve Work Outcomes in Schizophrenia January 2005 February 2010
NCT00269919 Completed Phase 4 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia August 2005 August 2008
NCT00283179 Completed Phase 3 Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia March 2004 December 2004
NCT00287352 Completed Phase 1 Study of Amantadine for Weight Stabilization During Olanzapine Treatment May 2005 September 2009
NCT00288340 Completed N/A Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging January 2006 August 2006
NCT00288366 Completed N/A Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome January 2006 December 2008
NCT00297388 Completed Phase 3 A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder September 2004
NCT00297947 Completed Phase 2/Phase 3 High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder December 2004 October 2014
NCT00303602 Completed Phase 4 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) March 2006 December 2007
NCT00304655 Completed Phase 4 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) July 2004 October 2007
NCT00306475 Completed Phase 4 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? March 2006 April 2008
NCT00312598 Completed Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine August 2005 April 2010
NCT00313391 Completed Phase 4 Risperdal Consta and Health Care Utilization in Patients With Schizophrenia December 2005
NCT00316303 Completed Phase 2 Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder February 2006 August 2012
NCT00320697 Completed Phase 4 Smoking Relapse Prevention in Schizophrenia April 2006 August 2009
NCT00320723 Completed Phase 4 Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia July 2001 December 2005
NCT00320736 Completed Phase 4 Galantamine for Cognition in People With Schizophrenia January 2004 May 2006
NCT00325689 Completed Phase 4 Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. July 2006 October 2007
NCT00330863 Completed Phase 4 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy May 2006 January 2011
NCT00337662 Completed Phase 4 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia May 2006 December 2007
NCT00349973 Completed N/A Clinical Trial of Dipyridamole in Schizophrenia May 2001 September 2011
NCT00350883 Completed Phase 2 Cognitive Therapy for Negative Symptoms and Functioning July 2006 November 2011
NCT00357006 Completed Phase 2 A Definitive Estrogen Patch Study (ADEPT) July 2006 December 2013
NCT00361543 Completed Phase 4 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia August 2006 December 2014
NCT00362804 Completed N/A Tetrabenazine for Partial Responders February 2002 January 2006
NCT00369239 Completed Phase 4 Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis March 2006 November 2007
NCT00373126 Completed Phase 4 The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia April 2005
NCT00373672 Completed Phase 4 Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder August 2006 January 2010
NCT00378183 Completed Phase 4 A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine. February 2001 May 2002
NCT00391261 Completed Phase 4 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. July 2006 October 2007
NCT00395031 Completed Phase 2/Phase 3 Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder September 2003 January 2010
NCT00397033 Completed Phase 3 Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. November 2006 February 2008
NCT00399334 Completed PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders June 2005 December 2005
NCT00400166 Completed N/A Recovery Guide Intervention for Recurrent Psychiatric Hospitalization December 2006 May 2009
NCT00401089 Completed Phase 1/Phase 2 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia December 2002 October 2007
NCT00403247 Completed N/A Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia July 2004 July 2007
NCT00406315 Completed Phase 4 Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone November 2006 March 2009
NCT00406718 Completed N/A Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia November 2006 July 2013
NCT00407277 Completed N/A Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia February 2007
NCT00412373 Completed Phase 3 Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder. December 2006 June 2008
NCT00419146 Completed Phase 2/Phase 3 Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants September 2001 April 2004
NCT00421954 Completed Phase 3 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents May 2006 May 2009
NCT00423878 Completed Phase 4 Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder January 2007 March 2010
NCT00423943 Completed Phase 4 Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia September 2005 December 2012
NCT00430560 Completed Phase 2/Phase 3 Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia October 2000 October 2015
NCT00431184 Completed Phase 2 Effects of Pentazocine Versus Lorazepam on Manic Symptoms January 2007 March 2011
NCT00434980 Completed N/A Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia February 2005 February 2015
NCT00453609 Completed Phase 4 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) April 2007 October 2008
NCT00458211 Completed Phase 4 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics May 2005 April 2008
NCT00458367 Completed RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice June 2002 October 2006
NCT00466323 Completed N/A The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. September 2007 June 2011
NCT00470106 Completed N/A Improving Basic and Social Cognition in Veterans With Schizophrenia September 2007 September 2009
NCT00480571 Completed Phase 2 Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder June 2007 December 2007
NCT00492349 Completed Phase 4 Varenicline Adjunctive Treatment in Schizophrenia May 2007 April 2011
NCT00498550 Completed Phase 4 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual October 2000 March 2009
NCT00499044 Completed N/A A Comparison of Two Cognitive Batteries in People With Schizophrenia December 2007 March 2009
NCT00500695 Completed Phase 1 Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness May 2006 October 2013
NCT00501618 Completed Phase 4 Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder November 2006 July 2009
NCT00507988 Completed N/A Complex Problem Solving Training in Schizophrenic Patients August 2007 February 2009
NCT00514423 Completed N/A How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs September 2006 December 2011
NCT00514449 Completed Phase 2 Systematic Evaluation of Antiviral Medication in Schizophrenia June 2007 September 2016
NCT00515723 Completed N/A Glucose and Lipid Metabolism on Antipsychotic Medication September 2001 December 2008
NCT00520650 Completed Phase 4 Health Evaluation of Abilify Long-term Therapy August 2006 April 2009
NCT00522613 Completed N/A Recovery Group Pilot July 2005 December 2006
NCT00523783 Completed Seroquel Long-Term NIS for Schizophrenia Patients May 2007 May 2008
NCT00535145 Completed Phase 4 Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease October 2007 February 2009
NCT00538122 Completed Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment July 2007 September 2008
NCT00538642 Completed N/A Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone August 2007 November 2011
NCT00539071 Completed Phase 4 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone March 2008 May 2012
NCT00545467 Completed Phase 4 Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents August 2007 July 2009
NCT00558298 Completed Phase 3 A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder. February 2000 February 2005
NCT00566735 Completed Phase 3 The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning July 2004 January 2008
NCT00588731 Completed Phase 2 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia February 2009 December 2013
NCT00595504 Completed Phase 4 Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia January 2008 March 2010
NCT00615511 Completed Phase 2 Efficacy of Pregnenolone in Patients With Schizophrenia June 2007 December 2014
NCT00621777 Completed Phase 4 A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder February 2008 May 2013
NCT00641745 Completed Phase 3 Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia March 2008 July 2010
NCT00644852 Completed Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone January 2007 September 2007
NCT00645944 Completed N/A Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia April 2008 April 2011
NCT00646581 Completed Phase 4 Effect of Single Dose Intranasal Insulin On Cognitive Function October 2006 January 2010
NCT00649064 Completed Phase 4 A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs December 2003 September 2004
NCT00650429 Completed Phase 4 A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder October 2003 May 2005
NCT00650611 Completed Phase 2 A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders December 2003 March 2005
NCT00661869 Completed N/A Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness September 2006 January 2008
NCT00683709 Completed Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder January 2007 July 2011
NCT00688259 Completed N/A Cognitive-Behavioral Therapy in Veterans With Schizophrenia April 2009 January 2015
NCT00688324 Completed Phase 4 Biomarker Study of Acamprosate in Schizophrenia June 2008 February 2012
NCT00690235 Completed Phase 4 Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia November 2007 August 2011
NCT00709202 Completed Phase 2 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain July 2008 December 2016
NCT00713804 Completed Phase 3 Impact of Genetic Counseling for Individuals With Mental Illness July 2008 November 2011
NCT00714818 Completed Phase 3 Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness August 2008 November 2011
NCT00716755 Completed N/A Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. October 2009 August 2015
NCT00727103 Completed Phase 4 Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia July 2008 May 2011
NCT00728728 Completed Phase 2 Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia December 2009 December 2015
NCT00749970 Completed Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia July 2008 January 2009
NCT00753506 Completed N/A Artemisinin to Reduce The Symptoms of Schizophrenia August 2008 May 2010
NCT00791349 Completed Phase 1 A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone February 2005 May 2005
NCT00791440 Completed N/A Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy November 2008 June 2012
NCT00791622 Completed Phase 1 A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine January 2006 June 2006
NCT00793780 Completed N/A Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia December 2008 November 2010
NCT00796081 Completed Phase 1 A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder January 2006 August 2006
NCT00796185 Completed Phase 1 As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations August 2003 January 2004
NCT00797277 Completed Phase 3 Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia July 2006 June 2009
NCT00817154 Completed Phase 1 Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) November 2009 December 2013
NCT00817336 Completed Phase 2 Biomarkers in Schizophrenia June 2009 July 2011
NCT00818298 Completed N/A 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study January 2009 June 2011
NCT00833976 Completed Phase 4 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia July 2009 March 2013
NCT00836251 Completed Effects of Antipsychotic Medications on Energy Intake and Expenditure April 2006 June 2008
NCT00864825 Completed Phase 4 Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia August 2009 January 2010
NCT00914238 Completed N/A Extended Specialized Assertive Intervention for First Episode Psychosis July 2009 October 2016
NCT00918021 Completed Phase 4 Polypharmacy in Clozapine-resistant Schizophrenia June 2009 July 2010
NCT00929955 Completed Phase 1 Role of Anti-Inflammatory Agents in Patients With Schizophrenia June 2009 September 2010
NCT00936351 Completed N/A Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia December 2007 December 2010
NCT00946348 Completed Phase 1 Cannabis and Schizophrenia: Self-Medication and Agonist Treatment December 2009 October 2012
NCT00960375 Completed Phase 2/Phase 3 Smoking Cessation for Veterans With Severe and Persistent Mental Illness April 2010 December 2014
NCT00981526 Completed Phase 4 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia March 2009 May 2012
NCT00990925 Completed N/A Lifestyle Modification for Weight Loss in Schizophrenia October 2009 February 2012
NCT00995553 Completed N/A Remediation of Working Memory in Schizophrenia January 2010 December 2015
NCT01001481 Completed Schizophrenia Treatment Adherence Investigation (STAI) July 2007 September 2009
NCT01004354 Completed N/A Vitamin D Supplementation in Psychiatric Illnesses June 2009 June 2010
NCT01028196 Completed Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression November 2009 November 2010
NCT01028677 Completed N/A Oxytocin Treatment of Schizophrenia November 2009 March 2011
NCT01029769 Completed N/A Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia December 2009 March 2015
NCT01036282 Completed Phase 4 Cognitive Skills Training Using Computer for Patients With Severe Mental Illness February 2003 December 2016
NCT01043250 Completed Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients May 2009 December 2010
NCT01065597 Completed Phase 1 Nonconvulsive Electrotherapy: a Proof-of-concept Trial May 2010 April 2014
NCT01075295 Completed N/A Prevention of Weight Gain in Early Psychoses February 2010 December 2012
NCT01092598 Completed Factors Association With Poor Physical Function in Older Adults With Schizophrenia March 2010 May 2015
NCT01093365 Completed Phase 2 Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia March 2010 August 2016
NCT01101464 Completed Phase 2 A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937) October 2002 December 2002
NCT01136772 Completed Phase 4 A Comparison of Long-acting Injectable Medications for Schizophrenia March 2011 July 2016
NCT01143077 Completed Phase 3 A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents June 2010 May 2011
NCT01143090 Completed Phase 3 A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder August 2010
NCT01169142 Completed Phase 4 Study of Vitamin D in the Severely Mentally Ill January 2010 December 2015
NCT01175642 Completed Early Phase 1 Cognitive Remediation and Functional Skills Training in Schizophrenia July 2007 September 2010
NCT01193153 Completed Phase 3 A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder September 2010 October 2013
NCT01196286 Completed N/A Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis June 2010 April 2017
NCT01198353 Completed Phase 4 Effectiveness of Ziprasidone for Patients With Schizophrenia September 2010 December 2013
NCT01216891 Completed N/A Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis October 2010 August 2016
NCT01242371 Completed N/A Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia August 2010 August 2012
NCT01248195 Completed Phase 4 Optimization of Treatment and Management of Schizophrenia in Europe May 2011 April 2016
NCT01259427 Completed Phase 2 Reducing Internalized Stigma in People With Serious Mental Illness October 2011 September 2015
NCT01269710 Completed Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study October 2009 March 2011
NCT01292577 Completed Phase 1/Phase 2 Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia September 2010 September 2014
NCT01309373 Completed An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia November 2010 August 2011
NCT01321177 Completed N/A An Integrated Program for the Treatment of First Episode of Psychosis July 2010 July 2017
NCT01339858 Completed Phase 4 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia May 2011 December 2015
NCT01384604 Completed Neurophysiological Studies in Schizophrenia and Psychiatric Disorders December 2007 May 2013
NCT01385709 Completed The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels August 2008 August 2013
NCT01394471 Completed Phase 1 Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia July 2011 January 2015
NCT01400477 Completed Phase 2 Nicotinic Receptors and Schizophrenia July 2011 June 2015
NCT01423916 Completed Phase 1 Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder July 2011 March 2012
NCT01425671 Completed Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States November 30, 2010 January 2024
NCT01425684 Completed Brain Circuits in Schizophrenia and Smoking December 20, 2010 April 2021
NCT01431092 Completed Phase 4 Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia October 2011 June 2014
NCT01450514 Completed Phase 2 POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia March 2012 December 2012
NCT01481883 Completed Phase 4 Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? January 2012 February 2019
NCT01487668 Completed N/A Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders December 2011 May 2015
NCT01490086 Completed Phase 2 RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder December 2011 March 2013
NCT01519557 Completed Early Phase 1 Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders April 2011 November 2013
NCT01521026 Completed N/A Cognitive Training for Patients With Schizophrenia September 2003 August 2009
NCT01542229 Completed N/A PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness) May 3, 2012 December 31, 2016
NCT01555814 Completed N/A Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen May 2011 October 2016
NCT01556763 Completed Phase 1 Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia April 2008 August 2008
NCT01561859 Completed N/A Brain Imaging, Cognitive Enhancement and Early Schizophrenia June 2012 June 2018
NCT01570972 Completed N/A Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis February 2010 April 2017
NCT01578486 Completed Phase 4 Salsalate as an Adjunctive Treatment for Patients With Schizophrenia June 2011 July 2015
NCT01596608 Completed N/A Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder February 2012 June 2019
NCT01602029 Completed Phase 2 Randomized Double Blind Placebo Control Study in Patients With Schizophrenia August 2010 June 2013
NCT01609153 Completed Phase 4 Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy June 2012 April 2019
NCT01658150 Completed N/A Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder September 2012 January 2, 2018
NCT01683539 Completed N/A Understanding How Cognitive Remediation Works September 2012 March 11, 2019
NCT01706965 Completed Phase 1/Phase 2 Kuvan in People With Schizophrenia and Schizoaffective Disorder October 2012 June 2016
NCT01731119 Completed Phase 2 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents December 2012 August 2014
NCT01731171 Completed N/A Probiotics to Prevent Relapse After Hospitalization for Mania November 2012 December 2016
NCT01752712 Completed N/A Oxytocin and CBSST for People With Schizophrenia January 2014 August 2016
NCT01780116 Completed Phase 1/Phase 2 Effectiveness of Adherence Therapy for Schizophrenia May 2013 February 2016
NCT04554121 Enrolling by invitation N/A Efficacy of Personalizing Cognitive Remediation for Schizophrenia by Targeting Impairments in Early Auditory Processing December 14, 2020 May 1, 2025
NCT05567848 Enrolling by invitation Phase 1/Phase 2 Accelerated TMS in Psychosis November 29, 2022 January 2025
NCT06251193 Not yet recruiting N/A Optimizing CBSST With Executive Function Training for Schizophrenia March 15, 2024 February 1, 2027
NCT06107764 Not yet recruiting N/A Cerebellar Modulation of Cognition in Psychosis April 2024 December 2029
NCT05416658 Not yet recruiting N/A Shared Decision Making for Antipsychotic Medications January 1, 2025 June 30, 2025
NCT03974620 Not yet recruiting N/A Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia December 1, 2024 December 30, 2024
NCT05974527 Not yet recruiting Phase 4 Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department September 1, 2023 June 30, 2026
NCT05457127 Not yet recruiting N/A Obstructive Sleep Apnea Treatment in Serious Mental Illness January 1, 2024 November 2026
NCT06286202 Not yet recruiting N/A Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial May 2024 July 2027
NCT04324944 Recruiting N/A Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness July 5, 2022 March 31, 2025
NCT05824117 Recruiting N/A Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education. October 18, 2022 March 31, 2025
NCT04013555 Recruiting Phase 1/Phase 2 The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia January 20, 2020 June 30, 2024
NCT01888627 Recruiting N/A Integrated Care in Psychotic Disorders With Severe Mental Illness May 2007 December 2025
NCT02639702 Recruiting Phase 4 Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia August 2016 December 2026
NCT05877716 Recruiting N/A EPI-MINN: Targeting Cognition and Motivation - National May 30, 2023 July 2025
NCT05805397 Recruiting N/A Effectiveness of Motivation Skills Training (MST) April 15, 2024 November 2025
NCT04414930 Recruiting Phase 2 Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia November 9, 2020 December 2024
NCT04226898 Recruiting Phase 2 Synbiotic Compound to Reduce Symptoms of Schizophrenia February 21, 2022 January 2025
NCT06003036 Recruiting N/A Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine December 1, 2023 September 2025
NCT05859698 Recruiting Phase 4 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia May 25, 2023 December 2024
NCT00178932 Recruiting N/A Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors November 1998 December 2023
NCT06423651 Recruiting N/A Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders September 1, 2022 December 31, 2025
NCT04497857 Recruiting N/A Academic-Community EPINET (AC-EPINET) March 16, 2022 August 31, 2024
NCT00942981 Recruiting Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography November 13, 2009
NCT05890183 Recruiting N/A Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode May 23, 2023 May 31, 2028
NCT06005766 Recruiting N/A The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care September 1, 2023 December 2026
NCT04144231 Recruiting N/A Cognitive Behavioral Therapy for Insomnia (CBT-I) in Schizophrenia(SLEEPINS) December 19, 2019 September 6, 2024
NCT06221852 Recruiting N/A Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder March 12, 2024 December 30, 2027
NCT04580134 Recruiting Phase 4 CLOZAPINE Response in Biotype-1 March 1, 2022 March 31, 2026
NCT06007105 Recruiting N/A SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities July 18, 2023 January 31, 2024
NCT05670197 Recruiting Service User and Staff Views on Digital Remote Monitoring for Psychosis November 1, 2022 December 31, 2023
NCT06071858 Recruiting N/A Enhanced Coordinated Specialty Care for Early Psychosis February 1, 2024 October 2028
NCT04857983 Recruiting Phase 2/Phase 3 Memantine Augmentation of Targeted Cognitive Training in Schizophrenia July 6, 2021 December 30, 2024
NCT06159322 Recruiting Characterizing Response to Antipsychotics in Schizophrenia January 1, 2023 January 30, 2024
NCT04916626 Recruiting N/A The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis May 6, 2021 September 2025
NCT05664594 Recruiting N/A State Representation in Early Psychosis - Project 4 July 31, 2022 March 31, 2025
NCT00001486 Recruiting Genetic Study of Schizophrenia July 15, 1995
NCT04986072 Recruiting Phase 2 Sodium Nitroprusside in Early Course Schizophrenia March 14, 2022 December 22, 2024
NCT03314129 Recruiting N/A Remediation of Visual Perceptual Impairments in People With Schizophrenia June 1, 2018 August 31, 2025
NCT05023252 Recruiting N/A Mobile Self-Tracking October 18, 2021 September 30, 2024
NCT05030272 Recruiting N/A Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings September 21, 2021 April 1, 2025
NCT06182787 Recruiting Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient May 18, 2022 January 19, 2024
NCT03708315 Recruiting Phase 2 BXCL501 for Agitation in Schizophrenia March 9, 2020 June 2025
NCT06002958 Recruiting N/A Horyzons: Implementation and Integration in Clinical Practice January 8, 2024 October 31, 2024
NCT05204407 Recruiting N/A Luteolin for the Treatment of People With Schizophrenia June 13, 2022 March 2025
NCT05538832 Recruiting Early Phase 1 Remote State Representation in Early Psychosis July 27, 2022 March 31, 2025
NCT05527210 Recruiting N/A Prebiotic Treatment in People With Schizophrenia January 25, 2023 January 31, 2026
NCT05208190 Recruiting Phase 4 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial March 17, 2022 February 28, 2027
NCT03495024 Recruiting Phase 4 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates January 1, 2019 June 30, 2020
NCT05273164 Recruiting N/A State Representation in Early Psychosis December 1, 2021 March 31, 2025
NCT05464563 Recruiting N/A Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia March 22, 2022 March 2025
NCT01392885 Recruiting Brain Health and Exercise in Schizophrenia July 2011 December 2026
NCT05380583 Recruiting N/A Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study May 19, 2022 June 30, 2025
NCT04298450 Recruiting N/A ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention September 21, 2020 December 2025
NCT00575848 Terminated Phase 1 Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia December 2007 October 2008
NCT02796144 Terminated Phase 4 MEtformin and Lorcaserin for WeighT Loss in Schizophrenia September 2016 February 14, 2020
NCT01913327 Terminated Phase 4 Antipsychotic Effects on Brain Function in Schizophrenia April 2013 January 2017
NCT00857818 Terminated Phase 3 Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome April 2009 March 2010
NCT00288353 Terminated Phase 3 Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes January 2006 December 2008
NCT01929889 Terminated Phase 4 Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia April 2012 October 2014
NCT02949232 Terminated Phase 4 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder July 2014 May 2019
NCT00975611 Terminated Phase 4 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation October 2009 January 2012
NCT00314327 Terminated Phase 4 Optimizing Response in Psychosis Study April 2006 November 2013
NCT02149823 Terminated Phase 1 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations September 2013 June 14, 2022
NCT02234752 Terminated Phase 2 Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia September 2014 July 2016
NCT01368458 Terminated N/A Conversion to Antipsychotic Monotherapy December 2007 July 2008
NCT00001198 Terminated Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia March 19, 1984 October 10, 2017
NCT01420575 Terminated N/A Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia October 2010 August 2012
NCT00511628 Terminated Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia July 2001 January 2003
NCT00211302 Terminated N/A Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS) August 2003 February 2006
NCT00515489 Terminated Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients November 2001 August 2002
NCT00517075 Terminated Phase 2 Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) September 2004 June 2011
NCT00169026 Terminated Phase 4 Alcoholism and Schizophrenia: Effects of Clozapine May 1999 January 2004
NCT00547118 Terminated Phase 2 The Effects of Rimonabant, on Weight and Metabolic Risk Factors November 2007 March 2009
NCT00211380 Terminated N/A Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI) August 2003 February 2006
NCT00591318 Terminated Phase 1/Phase 2 A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis October 10, 2007 March 17, 2011
NCT00617214 Terminated Schizophrenic Patients Taking Part in Integrated Care Program January 2008 December 2008
NCT02462473 Terminated Phase 2 A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry May 2015 January 2016
NCT02476708 Terminated N/A A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia February 11, 2016 August 24, 2017
NCT00645229 Terminated Phase 3 A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder September 2004 March 2005
NCT01624831 Terminated Social Cognition in Longstanding Psychosis November 2011 November 2015
NCT00681629 Terminated Phase 4 Schizophrenic Patients in Integrated Care July 2008 November 2008
NCT00701753 Terminated A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses May 2008 March 2009
NCT01764568 Terminated N/A Contrasting Group Therapy Methods for Psychosis January 2013 June 2022
NCT00715377 Terminated N/A Anticholinergic Burden in Schizophrenia June 2007 December 2011
NCT00734435 Terminated Phase 2 Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects September 2008 December 2008
NCT02159001 Unknown status N/A Electroconvulsive Therapy in Clozapine-resistant Schizophrenia June 2014 June 2018
NCT04093518 Unknown status Phase 3 Estradiol as add-on to Antipsychotics December 2, 2019 November 1, 2020
NCT01182012 Unknown status Phase 4 Reduction of Cardiovascular Risk in Severe Mental Illness August 2010 December 2012
NCT01729572 Unknown status N/A Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients January 2014 August 2015
NCT03576911 Unknown status N/A A Randomised Controlled Trial of Coenzyme Q10 in Patients With Schizophrenia and Schizoaffective Disorder November 2016 August 2019
NCT00300651 Unknown status Phase 3 Trial of Cognitive Behavioral Therapy for Schizophrenia March 2006 August 2009
NCT01398189 Unknown status N/A F-18 Altanserin PET Study of Patients Receiving Clozapine July 2011 July 2015
NCT01215383 Unknown status The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy November 2010
NCT00192582 Unknown status N/A AIMHI NT Relapse Prevention Trial July 2005 August 2007
NCT00885716 Unknown status N/A A Shared Decision Making Training for Inpatients With Schizophrenia May 2009
NCT00861003 Unknown status An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder April 2009 August 2010
NCT02337439 Unknown status N/A Perceptual Deficits in Schizophrenia August 2014 December 2018
NCT00138775 Unknown status Phase 2 Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia October 2004 October 2007
NCT01474395 Unknown status Phase 2 N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia March 2012 June 2013
NCT03261557 Unknown status N/A Cognitive Behavioral Social Skills Training in Early Onset Psychosis February 22, 2017 September 2020
NCT00686400 Unknown status A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia May 2008 May 2011
NCT03240380 Unknown status N/A Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric Care. May 1, 2017 June 30, 2019
NCT04551027 Unknown status N/A Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness September 2020 December 2021
NCT00825045 Unknown status N/A Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia December 2008 December 2020
NCT03005574 Unknown status N/A Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program January 2017 December 2020
NCT01546467 Unknown status N/A Cognitive Remediation in Early Phase Psychosis September 2009 December 2013
NCT04335916 Unknown status Survey on Pre-ECT Evaluation and ECT Application April 1, 2020 November 1, 2020
NCT00157313 Unknown status N/A Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis January 1998 December 2022
NCT01831986 Unknown status N/A Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders January 2011 December 2013
NCT02433717 Unknown status Phase 4 A Pharmacokinetic Study of Paliperidone ER April 2015 February 2016
NCT03919760 Unknown status Early Psychosis Intervention - Spreading Evidence-based Treatment January 3, 2020 May 31, 2024
NCT04123223 Unknown status N/A Comparing Cognitive Remediation Approaches for Schizophrenia November 1, 2019 July 2022
NCT01769014 Unknown status Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder January 2013 December 2013
NCT02986490 Unknown status N/A Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs September 2014 December 2017
NCT00789022 Unknown status Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment January 2009
NCT02529163 Unknown status N/A Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms August 2015 July 2019
NCT01320982 Unknown status Phase 3 Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder March 2011 July 2012
NCT00435721 Unknown status Phase 1 Families Coping With Mental Illness Program June 2002 August 2005
NCT02533232 Unknown status Phase 1 Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia August 30, 2022 December 30, 2022
NCT01324167 Unknown status Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia May 2010 April 2011
NCT02221635 Unknown status Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective March 2013 January 2015
NCT00465283 Unknown status Phase 4 Donepezil Double Blind Trial for ECT Memory Disfunction May 2007 January 2010
NCT00465920 Unknown status Phase 2 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis May 2007 April 2010
NCT02665611 Unknown status N/A Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence February 2016 January 2018
NCT00469664 Unknown status Phase 4 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia February 2000 December 2008
NCT01280305 Unknown status Phase 3 Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder March 2011 March 2013
NCT05140135 Withdrawn N/A Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy January 11, 2021 December 31, 2025
NCT02661347 Withdrawn N/A Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia February 2016 December 1, 2016
NCT00672464 Withdrawn Phase 4 Cardio Risk of Acute Schizophrenia Olanzapine Duke April 2008 February 2010
NCT00534898 Withdrawn Phase 3 Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
NCT02197286 Withdrawn Phase 2 Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia February 2015
NCT00440843 Withdrawn Phase 3 Zyprexa and Task Engagement in Schizophrenia February 2007 June 2012
NCT05338424 Withdrawn Exercise Target Brain Oscillations in Psychosis July 1, 2022 September 30, 2022
NCT03061136 Withdrawn Phase 4 Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia October 2016 October 2017
Disase is a (Disease Ontology)
DOID:2468
Cross Reference ID (Disease Ontology)
ICD10CM:F25
Cross Reference ID (Disease Ontology)
ICD9CM:295.7
Cross Reference ID (Disease Ontology)
MESH:D011618
Cross Reference ID (Disease Ontology)
NCI:C94378
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:231490005
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0036337